DBV Technologies SA
PAR:DBV
During the last 3 months DBV Technologies SA insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 8% over this period (open performance analysis).
The last transaction was made on
Jan 18, 2019
by
Pierre-Henri Benhamou
, who
sold
174.8k EUR
worth of 
DBV shares.
During the last 3 months DBV Technologies SA insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 8% over this period (open performance analysis).
The last transaction was made on
Jan 18, 2019
by
Pierre-Henri Benhamou
, who
sold
174.8k EUR
worth of DBV shares.
DBV Technologies SA
Glance View
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
